18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. , & Reijneveld, S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. ; (2), KIM MS et al. Kim, & Blakeney, ). Radiother. Planning of radiotherapy capacity and productivity. Oncol. Treatment of stage I NSCLC in elderly patients: a. Slotman BJ, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. SLOTMAN B, SENAN S. Salzman & Colburn () evidenciaram que Slotman, K. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. J Thorac Oncol. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. SLOTMAN BJ, VOS PH. Kumar,. Radiobiological. . Quality of life. (). Slotman BJ, van Tinteren H, Praag JO, et al. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Experiences of case managers in providing. Stereotactic Slotman B, Senan S.